Chronic obstructive pulmonary disease and lung cancer: Inflammation, the missing link

Therapy

Volumn 6, Issue 6, 2009, Pages 805-820

  Gibbons, Michael A ^a   Sethi, Tariq ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

COPD; Family history; Infection; Inflammation; Lung cancer; Screening

Indexed keywords

5 ETHOXYMETHOXY N HYDROXY 2 METHYL 4 (4 PHENOXYBENZAMIDO)PENTANAMIDE; ALPHAVBETA6 INTEGRIN; BATIMASTAT; BEVACIZUMAB; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; HYPOXIA INDUCIBLE FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MARIMASTAT; PRINOMASTAT; REBIMASTAT; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR; VASCULOTROPIN; WNT1 PROTEIN;

ADAPTIVE IMMUNITY; ALPHA 1 ANTITRYPSIN DEFICIENCY; APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RISK; CANCER SURVIVAL; CELL PROLIFERATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; DISEASE ASSOCIATION; DNA DAMAGE; DNA METHYLATION; DRUG EFFICACY; EPITHELIUM CELL; FAMILY HISTORY; GENE FUNCTION; HOMEOSTASIS; HOMOZYGOSITY; HUMAN; IMMUNE RESPONSE; INFECTION; INFLAMMATION; LUNG CANCER; LUNG EMPHYSEMA; LUNG NON SMALL CELL CANCER; MESENCHYME CELL; PHENOTYPE; PREVALENCE; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; TUMOR GROWTH;

EID: 70449650822     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/thy.09.77     Document Type: Review

References (165)

1. Devereux G: ABC of chronic obstructive pulmonary disease. BMJ 332, 1142-1144 (2006).
2. Centers for Disease Control and Prevention (CDC): Deaths from chronic obstructive pulmonary disease: United States, 2000-2005. MMWR Morb. Mortal. Wkly Rep. 57, 1229-1232 (2008).
3. Youlden DR, Cramb SM, Baade PD: The international epidemiology of lung cancer: geographical distribution and secular trends. J. Thorac. Oncol. 3, 819-831 (2008).
4. Proctor RN: Tobacco and the global lung cancer epidemic. Nat. Rev. Cancer 1, 82-86 (2001).
5. Skillrud DM, Offord KP, Miller RD: Higher risk of lung cancer in chronic obstructive pulmonary disease. Ann. Intern. Med. 105, 503-507 (1986). ■■First matched study demonstrating the higher risk of lung cancer in patients with chronic obstructive pulmonary disease (COPD).
6. Balkwill F, Mantovani A: Inflammation and cancer: back to Virchow? Lancet 357, 539-545 (2001). ■■Excellent review exploring the links between inflammation and cancer. (Pubitemid 32173595)
7. Coussens LM, Werb Z: Inflammation and cancer. Nature 420, 860-867 (2002).
8. Lowell FC, Franklin W, Michelson AL, Schiller IW: Chronic obstructive pulmonary emphysema; a disease of smokers. Ann. Intern. Med. 45, 268-274 (1956).
9. Doll R, Hill AB: Smoking and carcinoma of the lung; preliminary report. BMJ 2, 739-748 (1950). ■■Landmark paper highlighting the link between smoking and lung cancer.
10. Muller FH: Tabakmissbrauch und lungencarcinom Z. Krebsforsch. 49, 57-85 (1939).
11. Goldstein MJ, Snider GL, Liberson M, Poske RM: Bronchogenic carcinoma and giant bullous disease. Am. Rev. Respir. Dis. 97, 1062-1070 (1968).
12. Stoloff IL, Kanofsky P, Magilner L: The risk of lung cancer in males with bullous disease of the lung. Arch. Environ. Health 22, 163-167 (1971).
13. Davis AL: Bronchogenic carcinoma in chronic obstructive pulmonary disease. JAMA 235, 621-622 (1976).
14. Tockman MS, Anthonisen NR, Wright EC, Donithan MG: Airways obstruction and the risk for lung cancer. Ann. Intern. Med. 106, 512-518 (1987). ■■Study confirming the greater risk of lung cancer associated with COPD.
15. Anthonisen NR, Connett JE, Killey JP et al.: Effects of smoking intervention and the use of inhaled anticholinergic bronchodilator on the rate of decline in FEV1: lung health study. JAMA 272, 1497-1505 (1994).
16. Kishi K, Gurney JW, Schroeder DR et al.: The correlation of emphysema or airway obstruction with the risk of lung cancer: a matched case-controlled study. Eur. Respir. J. 19, 1093-1098 (2002). (Pubitemid 34649624)
17. de Torres JP, Bastarrika G, Wisnivesky JP et al.: Assessing the relationship between lung cancer risk and emphysema detected on low-dose CT of the chest. Chest 132, 1932-1938 (2007).
18. Wilson DO, Weissfeld JL, Fuhrman CR et al.: The Pittsburgh Lung Screening Study (PLuSS): outcomes within 3 years of a first computed tomography scan. Am. J. Respir. Crit. Care Med. 178, 956-961 (2008). ■Up-to-date study demonstrating the link between emphysema, airway obstruction and lung cancer.
19. Mayne ST, Buenconsejo J, Janerich DT: Previous lung disease and risk of lung cancer among men and women nonsmokers. Am. J. Epidemiol. 149, 13-20 (1999). (Pubitemid 29028857)
20. Yang P, Schwartz AG, McAllister AE et al.: Lung cancer risk in families of nonsmoking probands: heterogeneity by age at diagnosis. Genet. Epidemiol. 17, 253-273 (1999). (Pubitemid 29522200)
21. Cassidy A, Myles JP, Liloglou T et al.: Defining high-risk individuals in a population-based molecular-epidemiological study of lung cancer. Int. J. Oncol. 28, 1295-1301 (2006).
22. Turner MC, Chen Y, Krewski D et al.: COPD associated with lung cancer mortality in a prospective study of never smokers. Am. J. Respir. Crit. Care Med. 176, 285-290 (2007).
23. Cohen BH: Chronic obstructive pulmonary disease: a challenge in genetic epidemiology. Am. J. Epidemiol. 112, 274-288 (1980).
24. Sun Z, Yang P: Neutrophil elastase and α-1 antitrypsin: the role of imbalance in cancer development and progression: a review. Lancet Oncol. 5, 182-190 (2004). (Pubitemid 38262851)
25. Harris CC, Primack A, Cohen MH: Elevated α1-Antitrypsin serum levels in lung cancer patients. Cancer 34, 280-281 (1974).
26. Yang P, Sun Z, Krowka MJ et al.: α1-antitrypsin deficiency carriers, tobacco smoke, chronic obstructive pulmonary disease, and lung cancer risk. Arch. Intern. Med. 168, 1097-1103 (2008). (Pubitemid 351749227)
27. Tokuhata GK, Lilienfeld AM: Familial aggregation of lung cancer in humans. J. Natl Cancer Inst. 30, 289-312 (1963).
28. Johnson L, Mercer K, Greenbaum D et al.: Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410, 1111-1116 (2001). (Pubitemid 32391044)
29. Zanesi N, Mancini R, Sevignani C et al.: Lung cancer susceptibility in Fhit deficient mice is increased by Vhl haploinsufficiency. Cancer Res. 65, 6576-6582 (2005). (Pubitemid 41060693)
30. McDuffie HH: Clustering of cancer in families of patients with primary lung cancer. J. Clin. Epidemiol. 44, 69-76 (1991).
31. Wunsch-Filho V, Boffetta P, Colin D, Moncau JE: Familial cancer aggregation and the risk of lung cancer. Sao Paulo Med. J. 120, 38-44 (2002). (Pubitemid 43051593)
32. Bailey-Wilson JE, Amos CI, Pinney SM et al.: A major lung cancer susceptibility locus maps to chromosome 6q23-25. Am. J. Hum. Genet. 75, 460-474 (2004).
33. Amos CI, Wu X, Broderick P et al.: Genome- wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat. Genet. 40, 616-622 (2008). (Pubitemid 351601203)
34. Zienolddiny S, Campa D, Lind H et al.: Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. Carcinogenesis 27, 560-567 (2006). (Pubitemid 43372885)
35. Yang P, Schwartz AG, McAllister AE, Swanson GM, Aston CE: Lung cancer risk in families of nonsmoking probands: heterogeneity by age at diagnosis. Genet. Epidemiol. 17, 253-273 (1999). (Pubitemid 29522200)
36. Gorlova OY, Zhang Y, Schabath MB et al.: Never smokers and lung cancer risk: a case-control study of epidemiological factors. Int. J. Cancer 118, 1798 - 1804 (2006).
37. Gao Y, Goldstein AM, Consonni D et al.: Family history of cancer and nonmalignant lung diseases as risk factors for lung cancer. Int. J. Cancer 125, 146-152 (2009).
38. Passey RD: Some problems of lung cancer. Lancet 2, 107-112 (1962).
39. Houghton AM, Mouded M, Shapiro SD: Common origins of lung cancer and COPD. Nat. Med. 14, 1023-1024 (2008). ■Excellent commentary on the association between COPD and lung cancer.
40. Kim CF, Jackson EL, Woolfenden AE et al.: Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 121, 823-835 (2005). ■■First study demonstrating the potential role of bronchioalveolar stem cells in lung cancer.
41. Parimon T, Chien JW, Bryson CL, McDonell MB, Udris EM, Au DH: Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 175, 712-719 (2007). (Pubitemid 46536487)
42. Kiri VA, Fabbri LM, Davis KJ, Soriano JB: Inhaled corticosteroids and risk of lung cancer among COPD patients who quit smoking. Respir. Med. 103, 85-90 (2009).
43. Tan A, Yeh S-H, Liu C-J, Cheung C, Chen P-J: Viral hepatocarcinogenesis: from infection to cancer. Liver Int. 28, 175-188 (2008).
44. Carbone A, Gloghini A, Dotti G: EBV-associated lymphoproliferative disorders: classification and treatment. Oncologist 13, 577-585 (2008). (Pubitemid 351872874)
45. Take S, Mizuno M, Ishiki K et al.: Baseline gastric mucosal atrophy is a risk factor associated with the development of gastric cancer after Helicobacter pylori eradication therapy in patients with peptic ulcer diseases. J. Gastroenterol. 42(Suppl. 17), 21-27 (2007). (Pubitemid 46140359)
46. Sethi S, Maloney J, Grove L, Wrona C, Berenson CS: Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 173, 991-998 (2006).
47. Soler N, Ewig S, Torres A, Filella X, Gonzalez J, Zaubet A: Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur. Respir. J. 14, 1015-1022 (1999).
48. Sethi S, Murphy TF: Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N. Engl. J. Med. 359, 2355-2365 (2008).
49. Moghaddam SJ, Li H, Cho SN et al.: Promotion of lung carcinogenesis by chronic obstructive pulmonary disease-like airway inflammation in a K-ras-induced mouse model. Am. J. Respir. Cell Mol. Biol. 40, 443-453 (2009).
50. Sakuraba M, Hirama M, Hebisawa A, Sagara Y, Tamura A, Komatsu H: Coexistent lung carcinoma and active pulmonary tuberculosis in the same lobe. Ann. Thorac. Cardiovasc. Surg. 12, 53-55 (2006).
51. Oka K, Chan L: Inhibition and regression of atherosclerotic lesions. Acta Biochim. Pol. 52, 311-319 (2005).
52. Dacosta NA, Kinare SG: Association of lung carcinoma and tuberculosis. J. Postgrad. Med. 37, 185-189 (1991).
53. Zheng W, Blot WJ, Liao ML et al.: Lung cancer and prior tuberculosis infection in Shanghai. Br. J. Cancer 56, 501-504 (1987). (Pubitemid 17146360)
54. Nalbandian A, Yan BS, Pichugin A, Bronson RT, Kramnik I: Lung carcinogenesis induced by chronic tuberculosis infection: the experimental model and genetic control. Oncogene 28, 1928-1938 (2009).
55. Frisch M, Biggar RJ, Engels EA, Goedert JJ; AIDS-Cancer Match Registry Study Group: Association of cancer with AIDS-related immunosuppression in adults. JAMA 285, 1736-1745 (2001).
56. Parker MS, Leveno DM, Campbell TJ, Worrell JA, Carozza SE: AIDS-related bronchogenic carcinoma: fact or fiction? Chest 113, 154-161 (1998).
57. Tenholder MF, Jackson HD: Bronchogenic carcinoma in patients seropositive for human immunodeficiency virus. Chest 104, 1049-1053 (1993).
58. Herida M, Mary-Krause M, Kaphan R et al.: Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J. Clin. Oncol. 21, 3447-3453 (2003). (Pubitemid 46594077)
59. Hoffman PC, Mauer AM, Vokes EE: Lung cancer. Lancet 355, 479-485 (2000).
60. Doll R, Peto R: The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J. Natl Cancer Inst. 66, 1191-1308 (1981). (Pubitemid 11063920)
61. Wistuba II, Behrens C, Milchgrub S et al.: Comparison of molecular changes in lung cancers in HIV-positive and HIV-indeterminate subjects. JAMA 279, 1554-1559 (1998). (Pubitemid 28233011)
62. Schwela D: Air pollution and health in urban areas. Rev. Environ. Health 15, 13-42 (2000).
63. Emmendoerffer A, Hecht M, Boeker T, Mueller M, Heinrich U: Role of inflammation in chemical-induced lung cancer. Toxicol. Lett. 112-113, 185-191 (2000). (Pubitemid 30138122)
64. Coussens LM, Werb Z: Inflammation and cancer. Nature 420, 860-867 (2002).
65. Cook JA, Gius D, Wink DA, Krishna MC, Russo A, Mitchell JB: Oxidative stress, redox, and the tumor microenvironment. Semin. Radiat. Oncol. 14, 259-266 (2004). (Pubitemid 38903230)
66. Ito K, Ito M, Elliott WM et al.: Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N. Engl. J. Med. 352, 1967-1976 (2005).
67. Adenuga D, Yao H, March TH, Seagrave J, Rahman I: Histone deacetylase 2 is phosphorylated, ubiquitinated and degraded by cigarette smoke. Am. J. Respir. Cell Mol. Biol. 40, 464-473 (2009).
68. Yang SR, Chida AS, Bauter MR et al.: Cigarette smoke induces pro-inflammatory cytokine release by activation of NF-κB and post-translational modifications of histone deacetylase in macrophages. Am. J. Physiol. Lung Cell Mol. Physiol. 291, L46-L57 (2006).
69. Barnes PJ: Role of HDAC2 in the pathophysiology of COPD. Annu. Rev. Physiol. 71, 451-464 (2009).
70. Brock MV, Hooker CM, Ota-Machida E et al.: DNA methylation markers and early recurrence in stage I lung cancer. N. Engl. J. Med. 358, 1118-1128 (2008).
71. Schrump DS, Nguyen DM: Targeting the epigenome for the treatment and prevention of lung cancer. Semin. Oncol. 32, 488-502 (2005).
72. Gridelli C, Rossi A, Maione P: The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer. Crit. Rev. Oncol. Hematol. 68, 29-36 (2008).
73. Hakem R: DNA-damage repair; the good, the bad, and the ugly. EMBO J. 27, 589-605 (2008).
74. Koshiji M, To KK, Hammer S et al.: HIF-1α induces genetic instability by transcriptionally downregulating MutSa expression. Mol. Cell 17, 793-803 (2005). (Pubitemid 40386941)
75. Chang CL, Marra G, Chauhan DP et al.: Oxidative stress inactivates the human DNA mismatch repair system. Am. J. Physiol. Cell Physiol. 283, C148-C54 (2002). (Pubitemid 34670558)
76. Crosby ME, Kulshreshtha R, Ivan M, Glazer PM: MicroRNA regulation of DNA repair gene expression in hypoxic stress. Cancer Res. 69, 1221-1229 (2009).
77. Guo HH, Loeb LA: Tumbling down a different pathway to genetic instability. J. Clin. Invest. 112, 1793-1795 (2003).
78. Hogg JC, Chu F, Utokaparch S et al.: The nature of small-airway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med. 350, 2645-2653 (2004). (Pubitemid 38787999)
79. van der Strate BW, Postma DS, Brandsma CA et al.: Cigarette smoke-induced emphysema: a role for the B cell? Am. J. Respir. Crit. Care Med. 173, 751-758 (2006).
80. Voelkel N, Taraseviciene-Stewart L: Emphysema: an autoimmune vascular disease? Proc. Am. Thorac. Soc. 2, 23-25 (2005). (Pubitemid 40562959)
81. Lee SH, Goswami S, Grudo A et al.: Antielastin autoimmunity in tobacco smoking induced emphysema. Nat. Med. 13, 567-569 (2007). (Pubitemid 46828488)
82. Lin EY, Nguyen AV, Russell RG, Pollard JW: Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 193, 727-740 (2001).
83. Bunt SK, Sinha P, Clements VK et al.: Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J. Immunol. 176, 284-290 (2006). (Pubitemid 43023273)
84. Bunt SK, Yang L, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S: Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res. 67, 10019-10026 (2007). (Pubitemid 47621253)
85. Condeelis J, Pollard JW: Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124, 263-266 (2006). (Pubitemid 43121975)
86. Redente EF, Orlicky DJ, Bouchard RJ, Malkinson AM: Tumor signaling to the bone marrow changes the phenotype of monocytes and pulmonary macrophages during urethane-induced primary lung tumorigenesis in A/J mice. Am. J. Pathol. 170, 693-708 (2007).
87. Bauer AK, Dwyer-Nield LD, Hankin JA, Murphy RC, Malkinson AM: The lung tumor promoter, butylated hydroxytoluene (BHT), causes chronic inflammation in promotion-sensitive BALB/cByJ mice but not in promotion-resistant CXB4 mice. Toxicology 169, 1-15 (2001).
88. Bauer AK, Dwyer-Nield LD, Keil K, Koski K, Malkinson AM: Butylated hydroxytoluene (BHT) induction of pulmonary inflammation: a role in tumor promotion. Exp. Lung Res. 27, 197-216 (2001). (Pubitemid 32239293)
89. Stearman RS, Dwyer-Nield L, Grady MC, Malkinson AM, Geraci MW: A macrophage gene expression signature defines a field effect in the lung tumor microenvironment. Cancer Res. 68, 34-43 (2008).
90. Kim DW, Min HS, Lee KH et al.: High tumor islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected non-small cell lung cancer. Br. J. Cancer 98, 1118-1124 (2008).
91. Grunert S, Jechlinger M, Beug H: Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat. Rev. Mol. Cell Biol. 4, 657-665 (2003). (Pubitemid 36934968)
92. Kalluri R, Neilson EG: Epithelial-mesenchymal transition and its implications for fibrosis. J. Clin. Invest. 112, 1776-1784 (2003). (Pubitemid 38063698)
93. Dohadwala M, Yang SC, Luo J et al.: Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in nonsmall cell lung cancer. Cancer Res. 66, 5338-5345 (2006). (Pubitemid 43844959)
94. Tarin D, Thompson EW, Newgreen DF: The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Res. 65, 5996-6000 (2005). (Pubitemid 40994379)
95. Thompson EW, Newgreen DF, Tarin D: Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition? Cancer Res. 65, 5991-5995 (2005).
96. Varjosalo M, Taipale J: Hedgehog signaling. J. Cell Sci. 120, 3-6, (2007).
97. van Tuyl M, Post M: From fruitflies to mammals: mechanisms of signalling via the Sonic hedgehog pathway in lung development. Respir. Res. 1, 30-35, (2000).
98. Watkins DN, Berman DM, Burkholder SG, Wang B, Beachy PA, Baylin SB: Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature 422, 313-317 (2003). (Pubitemid 36378358)
99. Yuan Z, Goetz JA, Singh S et al.: Frequent requirement of hedgehog signaling in non-small cell lung carcinoma. Oncogene 26, 1046-1055 (2007). (Pubitemid 46272210)
100. Nusse R, Varmus HE: Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 31, 99-109 (1982).
101. Katoh M: Expression and regulation of WNT1 in human cancer: up-regulation of WNT1 by β-estradiol in MCF-7 cells. Int. J. Oncol. 22, 209-212 (2003).
102. Wong SC, Lo SF, Lee KC, Yam JW, Chan JK, Wendy Hsiao WL: Expression of frizzled-related protein and Wnt-signalling molecules in invasive human breast tumors. J. Pathol. 196, 145-153 (2002).
103. Chen S, Guttridge DC, You Z et al.: Wnt-1 signaling inhibits apoptosis by activating β-catenin/T cell factor-mediated transcription. J. Cell Biol. 152, 87-96 (2001). (Pubitemid 32102439)
104. He B, You L, Uematsu K et al.: A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells. Neoplasia 6, 7-14 (2004). (Pubitemid 38391944)
105. You L, He B, Xu Z et al.: Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells. Oncogene 23, 6170-6174 (2004). (Pubitemid 39178870)
106. Collins BJ, Kleeberger W, Ball DW: Notch in lung development and lung cancer. Semin. Cancer Biol. 14, 357-364 (2004).
107. Chen H, Thiagalingam A, Chopra H et al.: Conservation of the Drosophila lateral inhibition pathway in human lung cancer: a hairy-related protein (HES-1) directly represses achaete-scute homolog-1 expression. Proc. Natl Acad. Sci. USA 94, 5355-5360 (1997). (Pubitemid 27214787)
108. Konishi J, Kawaguchi KS, Vo H et al.: γ-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers. Cancer Res. 7, 8051-8057 (2007). (Pubitemid 47395139)
109. Huber MA, Kraut N, Beug H: Molecular requirements for epithelia-mesenchymal transition during tumor progression. Curr. Opin. Cell Biol. 17, 548-558 (2005). (Pubitemid 41267170)
110. Gotzmann J, Mikula M, Eger A et al.: Molecular aspects of epithelial cell plasticity: implications for local tumor invasion and metastasis. Mutat. Res. 566, 9-20 (2004). (Pubitemid 38045586)
111. Yingling JM, Blanchard KL, Sawyer JS: Development of TGF-β signalling inhibitors for cancer therapy. Nat. Rev. Drug Discov. 3, 1011-1022 (2004).
112. Sethi T, Rintoul RC, Moore SM et al.: Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat. Med. 5, 662-668 (1999). (Pubitemid 29289430)
113. Houghton AM, Quintero PA, Perkins DL et al.: Elastin fragments drive disease progression in a murine model of emphysema. J. Clin. Invest. 116, 753-759 (2006).
114. van Houwelingen AH, Weathington NM, Verweij V, Blalock JE, Nijkamp FP, Folkerts G: Induction of lung emphysema is prevented by L-arginine-threonine- arginine. FASEB J. 22, 3403-3408 (2008).
115. Bonomi P: Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer. Semin. Oncol. 29, 78-86 (2002).
116. Liu J, Tsao MS, Pagura M et al.: Early combined treatment with carboplatin and the MMP inhibitor, prinomastat, prolongs survival and reduces systemic metastasis in an aggressive orthotopic lung cancer model. Lung Cancer 42, 335-344 (2003). (Pubitemid 37468547)
117. Yamamoto A, Yano S, Shiraga M et al.: A third-generation matrix metalloproteinase (MMP) inhibitor (ONO-4817) combined with docetaxel suppresses progression of lung micrometastasis of MMP expressing tumor cells in nude mice. Int. J. Cancer 103, 822-828 (2003). (Pubitemid 36110241)
118. Kim S, Takahashi H, Lin WW et al.: Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 457, 102-106 (2009). ■Elegant study highlighting the importance of extracellular matrix and an inflammatory microenvironment to lung cancer metastasis.
119. Pirinen R, Leinonen T, Böhm J: Versican in nonsmall cell lung cancer: relation to hyaluronan, clinicopathologic factors, and prognosis. Hum. Pathol. 36, 44-50 (2005). (Pubitemid 40220332)
120. Siafakas NM, Antoniou KM, Tzortzaki EG: Role of angiogenesis and vascular remodeling in chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 2, 453-462 (2007).
121. Michaud SE, Menard C, Guy LG, Gennaro G, Rivard A: Inhibition of hypoxia-induced angiogenesis by cigarette smoke exposure: impairment of the HIF-1α/ VEGF pathway. FASEB J. 17, 1150-1152 (2003).
122. Morris DG, Huang X, Kaminski N et al.: Loss of integrin α(v)β6-mediated TGF-β activation causes MMP12-dependent emphysema. Nature 422, 169-173 (2003). (Pubitemid 36362749)
123. Takizawa H, Tanaka M, Takami K et al.: Increased expression of transforming growth factor-β1 in small airway epithelium from tobacco smokers and patients with chronic obstructive pulmonary disease (COPD). Am. J. Respir. Crit. Care Med. 163, 1476-1483 (2001). (Pubitemid 32506619)
124. Karin M: Nuclear factor-κB in cancer development and progression. Nature 441, 431-436 (2006).
125. Pikarsky E, Porat RM, Stein I et al.: NF-κB functions as a tumor promoter in inflammation associated cancer. Nature, 431, 461-466 (2004). (Pubitemid 39329586)
126. Greten FR, Eckmann L, Greten TF et al.: IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118, 285-296 (2004). (Pubitemid 39061110)
127. Mauad TH, van Nieuwkerk CM, Dingemans KP et al.: Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. Am. J. Pathol. 145, 1237-1245 (1994).
128. Pikarsky E, Porat RM, Stein I et al.: NF-κB functions as a tumor promoter in inflammation-associated cancer. Nature 431, 461-466 (2004). (Pubitemid 39329586)
129. Lee WJ, Lu FJ, Wang SF, Chen YR, Tseng TH: In vitro enhancement effect of humic acid on the progression of lung cancer cells. Chem. Biol. Interact. 181, 463-471 (2009).
130. Ni J, Takayama K, Ushijima R et al.: Adenovirus-mediated inhibitor κB gene transfer improves the chemosensitivity to anticancer drugs in human lung cancer in vitro and in vivo. Anticancer Res. 28, 601-608 (2008). (Pubitemid 351578899)
131. Dey A, Wong ET, Bist P, Tergaonkar V, Lane DP: Nutlin-3 inhibits the NFκB pathway in a p53-dependent manner: implications in lung cancer therapy. Cell Cycle 6, 2178-2185 (2007). (Pubitemid 47450420)
132. Gradilone A, Silvestri I, Scarpa S et al.: Failure of apoptosis and activation on NFκB by celecoxib and aspirin in lung cancer cell lines. Oncol. Rep. 17, 823-828 (2007).
133. Yu CL, Meyer DJ, Campbell GS et al.: Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 269, 81-83 (1995).
134. Yu H, Jove R: The STATs of cancer - new molecular targets come of age. Nat. Rev. Cancer 4, 97-105 (2004). (Pubitemid 38198738)
135. Bromberg J, Darnell JE: The role of STATs in transcriptional control and their impact on cellular function. Oncogene 19, 2468-2473 (2000). (Pubitemid 30339202)
136. Welte T, Zhang SS, Wang T et al.: STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity. Proc. Natl Acad. Sci. USA 100, 1879-1884 (2003).
137. Kortylewski M, Kujawski M, Wang T et al.: Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat. Med. 11, 1314-1321 (2005). (Pubitemid 41752912)
138. Wang T, Niu G, Kortylewski M et al.: Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med. 10, 48-54 (2004). (Pubitemid 38524698)
139. Coffer PJ, Koenderman L, de Groot RP: The role of STATs in myeloid differentiation and leukemia. Oncogene 19, 2511-2522 (2000). (Pubitemid 30339207)
140. Kortylewski M, Jove R, Yu H: Targeting STAT3 affects melanoma on multiple fronts. Cancer Metastasis Rev. 24, 315-327 (2005). (Pubitemid 40922802)
141. Lin TS, Mahajan S, Frank DA: STAT signaling in the pathogenesis and treatment of leukemias. Oncogene 19, 2496-2504 (2000). (Pubitemid 30339205)
142. Bromberg JF, Horvath CM, Besser D, Lathem WW, Darnell JE: Stat3 activation is required for cellular transformation by v-src. Mol. Cell. Biol. 18, 2553-2558 (1998). (Pubitemid 28183425)
143. Turkson J, Bowman T, Garcia R, Caldenhoven E, De Groot RP, Jove R: Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol. Cell. Biol. 18, 2545-2552 (1998). (Pubitemid 28183424)
144. Catlett-Falcone R, Landowski TH, Oshiro MM et al.: Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10, 105-115 (1999). (Pubitemid 29077388)
145. Wei D, Le X, Zheng L et al.: Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 22, 319-329 (2003). (Pubitemid 36194328)
146. Niu G, Wright KL, Huang M et al.: Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21, 2000-2008 (2002). (Pubitemid 34270888)
147. Sumimoto H, Imabayashi F, Iwata T, Kawakami Y: The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J. Exp. Med. 203, 1651-1656 (2006). (Pubitemid 44036269)
148. Nabarro S, Himoudi N, Papanastasiou A et al.: Coordinated oncogenic transformation and inhibition of host immune responses by the PAX3-FKHR fusion oncoprotein. J. Exp. Med. 202, 1399-1410 (2005). (Pubitemid 41668742)
149. Gao J, McConnell MJ, Yu B et al.: MUC1 is a downstream target of STAT3 and regulates lung cancer cell survival and invasion. Int. J. Oncol. 35, 337-345 (2009).
150. Sordella R, Bell DW, Haber DA, Settleman J: Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305, 1163-1167 (2004). (Pubitemid 39100331)
151. Alvarez JV, Greulich H, Sellers WR, Meyerson M, Frank DA: Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res. 66, 3162-3168 (2006).
152. Song L, Turkson J, Karras JG, Jove R, Haura EB: Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene 22, 4150-4165 (2003). (Pubitemid 36876236)
153. Buettner R, Mora LB, Jove R: Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin. Cancer Res. 8, 945-954 (2002). (Pubitemid 35177340)
154. Dowlati A, Nethery D, Kern JA: Combined inhibition of epidermal growth factor receptor and JAK/STAT pathways results in greater growth inhibition in vitro than single agent therapy. Mol. Cancer Ther. 4, 459-463 (2004). (Pubitemid 39193723)
155. Dowlati A, Kluge A, Nethery D, Halmos B, Kern JA: SCH66336, inhibitor of protein farnesylation, blocks signal transducer and activators of transcription 3 signaling in lung cancer and interacts with a small molecule inhibitor of epidermal growth factor receptor/ human epidermal growth factor receptor 2. Anticancer Drugs 19, 9-16 (2008). (Pubitemid 350190963)
156. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B: An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl Acad. Sci. USA 72, 3666-3670 (1975).
157. Moore RJ, Owens DM, Stamp G et al.: Mice deficient in tumor necrosis factor-a are resistant to skin carcinogenesis. Nat. Med. 5, 828-831 (1999). (Pubitemid 29318619)
158. Arnott CH, Scott KA, Moore RJ, Robinson SC, Thompson RG, Balkwill FR: Expression of both TNF-α receptor subtypes is essential for optimal skin tumor development. Oncogene 23, 1902-1910 (2004).
159. Tomita Y, Yang X, Ishida Y et al.: Spontaneous regression of lung metastasis in the absence of tumor necrosis factor p55. Int. J. Cancer 112, 927-933 (2004). (Pubitemid 39506997)
160. Kitakata H, Nemoto-Sasaki Y, Takahashi Y, Kondo T, Mai M, Mukaida N: Essential roles of tumor necrosis factor receptor p55 in liver metastasis of intrasplenic administration of colon 26 cells. Cancer Res. 62, 6682-6687 (2002). (Pubitemid 35364138)
161. Hosomi Y, Yokose T, Hirose Y et al.: Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung. Lung Cancer 30, 73-81 (2000). (Pubitemid 30845546)
162. Wolff H, Saukkonen K, Anttila S et al.: Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res. 58, 4997-5001 (1998). (Pubitemid 28521147)
163. Achiwa H, Yatabe Y, Hida T et al.: Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin. Cancer Res. 5, 1001-1005 (1999). (Pubitemid 29233213)
164. Khuri FR, Wu H, Lee JJ et al.: Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin. Cancer Res. 7, 861-867 (2001). (Pubitemid 32708722)
165. Schreinemachers DM, Everson RB: Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5, 138-146 (1994).